These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22226866)

  • 1. Role of the PPAR-α agonist fenofibrate in severe pediatric burn.
    Elijah IE; Børsheim E; Maybauer DM; Finnerty CC; Herndon DN; Maybauer MO
    Burns; 2012 Jun; 38(4):481-6. PubMed ID: 22226866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.
    Belfort R; Berria R; Cornell J; Cusi K
    J Clin Endocrinol Metab; 2010 Feb; 95(2):829-36. PubMed ID: 20061429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.
    Cree MG; Zwetsloot JJ; Herndon DN; Qian T; Morio B; Fram R; Sanford AP; Aarsland A; Wolfe RR
    Ann Surg; 2007 Feb; 245(2):214-21. PubMed ID: 17245174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.
    Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA
    Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.
    Park CW; Zhang Y; Zhang X; Wu J; Chen L; Cha DR; Su D; Hwang MT; Fan X; Davis L; Striker G; Zheng F; Breyer M; Guan Y
    Kidney Int; 2006 May; 69(9):1511-7. PubMed ID: 16672921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.
    Gauglitz GG; Herndon DN; Jeschke MG
    J Burn Care Res; 2008; 29(5):683-94. PubMed ID: 18695610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.
    Srivastava RA; Jahagirdar R; Azhar S; Sharma S; Bisgaier CL
    Mol Cell Biochem; 2006 Apr; 285(1-2):35-50. PubMed ID: 16477380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
    Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
    Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
    Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
    J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial.
    Black RN; Ennis CN; Young IS; Hunter SJ; Atkinson AB; Bell PM
    J Diabetes Complications; 2014; 28(3):323-7. PubMed ID: 24560135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combined PPAR-γ and PPAR-α agonist therapy on fructose induced NASH in rats: Modulation of gene expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    Eur J Pharmacol; 2016 Feb; 773():59-70. PubMed ID: 26825546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fenofibrate in clinical practice.
    Zambon A; Cusi K
    Diab Vasc Dis Res; 2007 Sep; 4 Suppl 3():S15-20. PubMed ID: 17935056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of hyperglycemia in burned patients: evidence-based studies.
    Mecott GA; Al-Mousawi AM; Gauglitz GG; Herndon DN; Jeschke MG
    Shock; 2010 Jan; 33(1):5-13. PubMed ID: 19503020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
    Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
    J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
    Srivastava RA; He S
    Mol Cell Biochem; 2010 Dec; 345(1-2):197-206. PubMed ID: 20740305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrates: therapeutic potential for diabetic nephropathy?
    Kouroumichakis I; Papanas N; Zarogoulidis P; Liakopoulos V; Maltezos E; Mikhailidis DP
    Eur J Intern Med; 2012 Jun; 23(4):309-16. PubMed ID: 22560376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.
    Kasai S; Inoue T; Yoshitomi H; Hihara T; Matsuura F; Harada H; Shinoda M; Tanaka I
    J Pharmacol Sci; 2008 Sep; 108(1):40-8. PubMed ID: 18776709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.
    Varghese Z; Moorhead JF; Ruan XZ
    Kidney Int; 2006 May; 69(9):1490-1. PubMed ID: 16672917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.